Sensus Healthcare, Inc. (SRTS)

Executive Summary / Key Takeaways

• The CPT Code Catalyst: First-ever dedicated reimbursement codes for superficial radiation therapy, effective January 1, 2026, represent a significant per-fraction increase that eliminates a major barrier to SRT adoption. This transforms Sensus from a company navigating reimbursement ambiguity into one with clear physician economics, directly addressing the customer concentration and sales volatility seen in 2025.

• Fair Deal Agreement as Recurring Revenue Moat: The FDA program grew revenue significantly in 2025 while increasing treatment volumes eightfold, creating a contractual percentage-of-collections model that aligns Sensus's interests with patient utilization. This shifts the business from lumpy capital equipment sales to predictable recurring revenue, with 18 active sites and 10 pending activation providing a foundation for 2026 profitability.

• 2025: Transition Year, Not Structural Decline: The $14.3 million revenue drop and $7.7 million net loss stemmed from a temporary LCD proposal that paused domestic sales and a major customer's reimbursement uncertainty. These were external shocks, not competitive erosion. The company maintained $22.1 million in cash with zero debt, positioning it to capitalize on the new reimbursement clarity.

• Multiple Growth Vectors Activated: With MDSAP certification opening Canada, Brazil, Japan, and Australia, international sales could grow from 5-10% to 20% of revenue within 24 months. The Sensus Link platform and Sentinel 2.0 analytics create upsell opportunities across the 900+ system installed base, while the new ROS partnership penetrates hospital-based oncology.

• Execution Risk Defines the Asymmetry: The thesis hinges on management's ability to scale a newly expanded sales force, convert the FDA pipeline, and diversify away from a customer that represented 52% of 2025 revenue. Successful execution unlocks a combination of reimbursement tailwinds, recurring revenue, and operating leverage in a market with over 3.5 million annual diagnoses.

Setting the Scene: The Reimbursement Overhang That Defined a Decade

Sensus Healthcare, founded in 2010 and headquartered in Boca Raton, Florida, built its business around a simple proposition: non-melanoma skin cancer patients deserve a non-surgical treatment option that doesn't leave scars. The company's superficial radiation therapy (SRT) systems—the SRT-100, SRT-100+, and SRT-100 Vision—deliver low-energy photon x-rays that eliminate basal cell and squamous cell carcinomas without anesthesia or grafting. This matters because the American Academy of Dermatology estimates over 3.5 million Americans are diagnosed annually, nearly double all other cancers combined, creating a massive addressable market for office-based treatments.

The business model appears straightforward: sell capital equipment to dermatology practices, generate recurring revenue from consumables and service contracts, and capture a percentage of reimbursement through innovative operational partnerships. Yet for years, two factors weighed heavily on the investment case: extreme customer concentration and the absence of dedicated CPT codes . This created a reimbursement gray area where physicians faced claim denials and payment delays. The company's largest customer accounted for 73% of revenue in 2024 and 52% in 2025, making Sensus sensitive to the purchasing patterns of a single entity. This concentration risk explains why the stock traded at lower multiples despite achieving profitability from 2021 through 2024.

The industry structure reveals why reimbursement clarity is the linchpin. SRT competes against Mohs surgery, cryotherapy, and topical treatments, but its true competition is the status quo of surgical excision. Without clear physician economics, Sensus remained a niche alternative rather than a standard of care. The company's 2025 challenges—a proposed Local Coverage Determination questioning ultrasound reimbursement, a major customer's temporary pause, and lobbying costs that increased R&D expenses by 86%—were symptoms of this underlying environment. The LCD proposal didn't question the technology's efficacy; it questioned the frequency of ultrasound use, creating just enough uncertainty to freeze purchasing decisions. This demonstrates how reimbursement ambiguity, not product quality, drove the 34% revenue decline and $7.7 million loss.

Technology, Products, and Strategic Differentiation: Beyond the Box

Sensus's core technology advantage lies in its integrated ultrasound imaging, which transforms SRT from a blind radiation delivery system into an image-guided precision therapy. The SRT-100 Vision's embedded high-frequency ultrasound module enables volumetric tumor analysis, beam margin planning, and real-time dosimetry , allowing physicians to see lesions shrink over time. This matters because clinical data shows image-guided SRT improves cure rates, and patients value seeing the lesion shrinking, creating a powerful word-of-mouth marketing engine. The technology's differentiation fundamentally changes the risk-reward calculation for treating lesions in cosmetically sensitive areas where scarring is unacceptable.

The proposed LCD in Q2 2025 targeted this exact advantage, questioning whether ultrasound reimbursement should be limited. Management's response—presenting evidence to CMS that imaging improves outcomes—reveals a crucial insight: the challenge was addressed by noting that radiation oncology typically supports imaging before every fraction of treatment. CMS's subsequent decision to grant a dedicated ultrasound code validated this defense. The new CPT codes don't just increase reimbursement; they codify ultrasound's clinical necessity, permanently removing this risk.

The Fair Deal Agreement (FDA) program represents Sensus's most strategic innovation. Rather than selling equipment outright, Sensus provides a turnkey solution: the SRT system, certified radiotherapy technologists, and radiation oncology oversight in exchange for a contractual percentage of reimbursement. This model aligns incentives—Sensus profits only when patients are treated, creating a recurring revenue stream that grows with utilization. In 2025, FDA revenue surged 588% to $1.72 million, treatments increased eightfold, and patient volumes rose 250%. This transforms the business from capital equipment sales to a healthcare services platform with predictable recurring revenue. The 18 active sites and 10 pending activations represent a compounding revenue base for 2026, providing a floor under earnings even if equipment sales remain volatile.

The Sentinel software platform adds another layer of differentiation. This HIPAA-compliant system enables remote diagnostics, real-time support, and treatment volume monitoring for FDA sites. The Sentinel 2.0 upgrade, expected in 2026, will deliver deeper utilization analytics and practice-level visibility, particularly valuable for private equity-backed dermatology platforms seeking to standardize care and optimize economics. This creates switching costs and data network effects. Once a practice's operational data flows through Sentinel, migrating to a competitor requires not just new hardware but operational disruption and loss of historical analytics.

Sensus Link, launched in February 2026, extends advanced capabilities to the base SRT-100 installed base. This cloud-based solution brings workflow enhancements and treatment documentation to older systems, creating an upsell opportunity across the 900+ units already in the field. This monetizes the installed base without requiring hardware replacement, improving return on past sales investments and creating a software-like recurring revenue stream.

Financial Performance & Segment Dynamics: 2025 as a Bridge Year

The 2025 financial results tell a story of transition. Revenue fell 34% to $27.5 million, driven by a 45.7% drop in point-in-time product sales from 115 units in 2024 to 70 units in 2025. Gross margin compressed from 58.4% to 43.3%, a $12.5 million absolute decline. These numbers are contextualized by the fact that the shortfall was largely tied to a single customer's pause and the LCD-induced market freeze. The company maintained its market position while the broader market paused.

The balance sheet reveals management's strategic positioning. Cash remained at $22.1 million with zero debt, while accounts receivable plummeted 70% to $6 million, reflecting both lower sales and the concentration risk that management is actively addressing. Inventories increased 44% to $14.6 million, a deliberate buildup anticipating a 2026 demand surge. This shows management was preparing for the reimbursement-triggered demand they believed was coming. The credit facility default on a minimum profitability covenant occurred, but with no outstanding borrowings and compliance restored, it is a historical footnote.

The segment mix shift is a significant financial story. While direct equipment sales declined, service revenue grew 29.6% and the FDA program grew 588%. This demonstrates the business model's evolution toward recurring revenue. The FDA program's $1.72 million in 2025 revenue represents 6.3% of total revenue but grew from a negligible base. With utilization increasing 157% since launch, this segment could represent 15-20% of revenue within two years, improving margin stability.

R&D expenses increased 86% to $7.8 million, driven by $3.6 million in lobbying costs for CPT code advocacy. This represents a one-time investment in regulatory infrastructure that removes the reimbursement barrier. Management expects 2026 R&D to be lower, which combined with revenue recovery should drive operating leverage and margin expansion.

Outlook, Management Guidance, and Execution Risk

Management's 2026 guidance reflects confidence following the $7.7 million loss in 2025. They expect Q1 2026 revenue to exceed Q4 2025 levels even without contribution from the historically largest customer, full-year profitability, and sequential revenue acceleration throughout the year. This signals that the CPT code change has already unlocked pent-up demand independent of the problematic large customer.

The reimbursement math supports this optimism. The new codes increase per-fraction reimbursement by over 300%, narrowing the gap between office-based and hospital outpatient rates. For a typical treatment course, this could increase physician reimbursement from approximately $1,500 to $6,000, transforming the ROI calculation. This converts SRT from an optional addition to a primary revenue driver for dermatology practices. Management notes the SRT-100 base model will see particular benefit due to its lower cost, potentially improving Sensus's margins as customers opt for the simpler system.

The sales force expansion strategy reveals the execution plan. Having added one rep in Q1 2026 with plans for three to five more, Sensus is taking a disciplined approach to scaling. The refined trade show strategy—focusing on high-quality lead generation—suggests a data-driven approach to customer acquisition that could improve sales efficiency.

International expansion provides a second growth vector. MDSAP certification , obtained in Q2 2025, unlocks Canada, Brazil, Japan, and Australia through a single audit. With six systems shipped internationally in Q4 2025 and China remaining the largest market, management targets 20% of revenue from international within 12-24 months, up from 5-10%. International sales often carry lower installation and servicing costs, improving margins while diversifying geographic concentration.

The Fair Deal Agreement pipeline adds a third vector. Management anticipates signing three to five additional multi-site FDA customers in 2025, with the 10 pending activations representing near-term revenue. Each new site compounds recurring revenue while de-risking the model. However, with the new reimbursement clarity, larger customers may prefer outright purchases over revenue-sharing agreements, creating a strategic tension between immediate sales and long-term recurring revenue.

Competitive Context and Positioning: David vs. Goliaths

Sensus competes in a bifurcated market against larger radiation oncology players. iCAD's (ICAD) Xoft electronic brachytherapy system holds a notable position in dermatology, generating $4.9 million quarterly revenue with 86% gross margins. This demonstrates the margin potential Sensus can target as it scales and shifts toward higher-margin service revenue. iCAD's focus on AI-integrated detection and broader oncology applications creates a less specialized competitor, while Sensus's dermatology-specific focus and ultrasound integration provide clinical differentiation.

Eckert & Ziegler's (EUZ.DE) 49% gross margins and 25% operating margins, driven by diversified isotope sales, show what scale and product breadth can achieve. This highlights Sensus's primary vulnerability: small scale leading to higher per-unit costs. However, Eckert's isotope dependency creates supply chain risks that Sensus's X-ray technology avoids, while Sensus's office-based focus targets a market segment that larger players like Elekta (EKTA.B), with its hospital-centric linear accelerators, cannot efficiently serve.

Elekta's 11.9% EBIT margins and global scale reflect its capabilities in AI-driven adaptive therapy. This shows the ultimate prize: becoming the standard of care across radiation oncology. Elekta's complexity and cost structure make it ill-suited for the ambulatory dermatology market that Sensus dominates, but its R&D investments in AI planning set a benchmark Sensus must eventually match. The Sentinel 2.0 program is Sensus's answer, aiming to provide practice-level analytics that compete with an ecosystem approach.

The key competitive insight is that Sensus's moat is built on market focus and regulatory clarity. While iCAD, Eckert & Ziegler, and Elekta spread resources across multiple indications, Sensus has pursued dermatology-specific FDA clearances and reimbursement codes. This creates a defensible niche where Sensus can achieve dominant share. The new CPT codes effectively wall off this niche by establishing SRT as a distinct modality.

Risks and Asymmetries: What Could Break the Thesis

Customer concentration remains a material risk. A single customer representing 52% of revenue creates vulnerability to purchasing policy changes. Even with new CPT codes, if this customer—likely a large dermatology platform—chooses to insource operations or switch to a competitor, Sensus could face another revenue cliff. Management's guidance excludes this customer, treating any return as upside, but the concentration risk won't fully resolve until the customer base diversifies.

Competitive response poses a second risk. iCAD's high gross margins and Elekta's AI capabilities mean well-capitalized rivals could develop dermatology-specific offerings if Sensus's CPT code success makes the market more attractive. Sensus's first-mover advantage in dedicated codes is regulatory; if competitors invest heavily in SRT-specific features, Sensus could face margin pressure. The mitigating factor is the installed base of 900+ systems creating switching costs.

Execution risk on sales force scaling could derail the 2026 profitability target. Adding three to five sales reps represents a significant increase in headcount, requiring effective training and lead generation. Sensus's historical success relied on a lean team; rapid expansion could increase SG&A faster than revenue if the new reps take longer to ramp in the post-CPT environment.

The TDI program's uncertain timeline represents a wildcard. Management describes it as a long program with FDA feedback expected by end of 2025, but the approval timeline is unclear. TDI could open a new $500 million+ aesthetic dermatology market, but continued delays burn R&D dollars without near-term return.

Valuation Context: Pricing the Turnaround

At $4.20 per share, Sensus trades at an enterprise value of $54.85 million, representing approximately 2.00x TTM revenue and 2.52x sales. This reflects the 2025 loss and revenue decline. The valuation creates asymmetry: if management executes on the 2026 profitability guidance, multiples could re-rate toward medtech averages of 3-4x sales, implying significant upside even without growth acceleration.

The balance sheet provides downside protection. With $22.1 million in cash, zero debt, and a current ratio of 9.72, Sensus has substantial runway. This eliminates immediate bankruptcy risk and provides strategic flexibility to invest through the CPT code ramp. The inventory build to $14.6 million represents prepared capacity for anticipated demand.

Comparative valuation highlights the opportunity. iCAD trades at 10.34x sales with 86% gross margins but negative operating margins. Eckert & Ziegler trades at 2.56x sales with 48% gross margins and 13% profit margins. Sensus at 2.52x sales with 43% gross margins and a path to profitability suggests the market hasn't yet priced in the margin recovery potential. The key difference is revenue growth trajectory: iCAD is flat, Eckert & Ziegler grew 5%, while Sensus is positioned for growth if CPT codes drive adoption.

The valuation's critical variable is the Fair Deal Agreement's contribution. If FDA revenue grows to $5-7 million in 2026 (representing 15-20% of a projected $35 million revenue base), the market may begin valuing Sensus on recurring revenue metrics. Recurring revenue often commands 4-6x sales multiples in medtech. The 18 active sites generating eightfold treatment growth provide early evidence this scaling is achievable.

Conclusion: A Show-Me Story With Asymmetric Upside

Sensus Healthcare enters 2026 with a combination of regulatory tailwinds, recurring revenue momentum, and balance sheet strength that could transform it from a volatile equipment supplier into a compound growth story. The new CPT codes validate SRT as a standard of care and remove the reimbursement uncertainty that capped adoption for years. This changes the company's risk profile from regulatory speculation to execution-dependent growth, a shift that typically commands a higher valuation multiple.

The investment thesis hinges on three variables: sales force execution, customer diversification, and competitive response. Management's guidance for Q1 revenue exceeding Q4 levels and full-year profitability provides a near-term catalyst to validate the CPT code impact. The Fair Deal Agreement's growth and international expansion via MDSAP provide multiple growth vectors that reduce dependence on any single customer. This creates a margin of safety: even if one vector underperforms, the others can drive the 2026 profitability target.

The asymmetry is notable. Downside is protected by $22 million in cash and zero debt, while upside could be significant if revenue re-accelerates and margins recover to historical levels. The key risk remains execution: scaling the sales force, converting the FDA pipeline, and diversifying the customer base before larger competitors respond. For investors willing to accept execution risk, Sensus offers exposure to a large annual market at an inflection point, with a recurring revenue model that could sustain growth for years. The CPT codes provide the fresh start; management must now prove they can capitalize on it.